Labcorp Holdings (LH)
NYSE:LH
Want to see LH full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
4.79Last Year’s EPS
4.35Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominately positive picture: solid top-line growth, double-digit EPS improvement, margin expansion, healthy BLS backlog and raised/narrowed guidance. Management highlighted strong progress on strategic partnerships, product launches and AI/technology initiatives. Key challenges include weather-driven volume disruption, Early Development transitional actions, regulatory/reimbursement uncertainty (CRUSH, PAMA/RESULTS Act), and modest short-term cash flow/leverage considerations. Overall, positives around organic growth, profitability and a robust deal/product pipeline outweigh the identified headwinds.Company Guidance
Enterprise Revenue Growth
Q1 enterprise revenue of $3.5 billion, up ~5.8% year-over-year (management cited ~6%), driven primarily by organic growth in Diagnostics and Central Labs.
Profitability and EPS Expansion
Adjusted operating margin expanded more than 30 basis points to 14.4% and adjusted EPS was $4.25, up 10.6% versus prior year.
Segment Strength – Diagnostics
Diagnostics revenue reached $2.8 billion, up 5.0%; organic revenue growth ~2.9%, total volume growth 2.5%, price/mix +2.6%; Diagnostics adjusted operating margin increased ~30 bps to 16.6%.
Segment Strength – Biopharma Laboratory Services (BLS)
BLS revenue $781 million, up 8.2% (includes ~5.5% FX benefit), organic growth 3.7%; Central Labs grew strongly (11% reported; ~4.9% organic constant currency); BLS adjusted operating margin improved ~60 bps to 15.5%.
Healthy BLS Backlog and Book-to-Bill
BLS backlog of $8.6 billion with approximately $2.7 billion expected to convert to revenue in the next 12 months; trailing 12-month book-to-bill remains healthy at 1.04.
Improved Cash Flow and Capital Deployment
Generated $71 million of free cash flow in Q1 (versus a use of $108 million prior year); invested $202 million in acquisitions and returned capital via $98 million share repurchases and $61 million dividends; ended quarter with $981 million cash and $700 million share repurchase authorization outstanding.
Raised and Narrowed Full-Year Guidance
Raised midpoint of enterprise revenue by ~$30 million and EPS midpoint by $0.13; full-year revenue growth guide of 5.0%–6.1%, adjusted EPS guidance $17.70–$18.35 (midpoint implies ~10% EPS growth), and free cash flow guidance $1.24B–$1.36B.
Strategic Partnerships, M&A and Product Launches
Announced nationwide collaboration with CHOP, completed acquisition of select Crouse Health assets and near-close on Parkview Health outreach assets; launched FDA-cleared Labcorp Fentanyl Urine Visual Test; expanded oncology companion diagnostics and other specialty testing capabilities.
Technology and Innovation Progress
Expanded AI and digital initiatives including PathAI digital pathology deployment, AWS/Datavant AI real-world data platform for Alzheimer's, Optum.ai collaboration to streamline operations, and MyLabcorp mobile app with AI assistant launching in May; recognized by Fortune and Ethisphere for innovation and ethics.
LH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $257.14 | $256.80 | -0.13% |
Feb 17, 2026 | $281.92 | $275.98 | -2.11% |
Oct 28, 2025 | $274.24 | $258.35 | -5.79% |
Jul 24, 2025 | $248.57 | $265.62 | +6.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Labcorp Holdings (LH) report earnings?
Labcorp Holdings (LH) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Labcorp Holdings (LH) earnings time?
Labcorp Holdings (LH) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LH EPS forecast?
LH EPS forecast for the fiscal quarter 2026 (Q2) is 4.79.